A Glimpse into the Role and Effectiveness of Splenectomy for Isolated Metachronous Spleen Metastasis of Colorectal Cancer Origin: Long-Term Survivals Can Be Achieved
Conclusions: Splenectomy is the optimal treatment for patients with isolated metachronous SM of CRC, with the laparoscopic approach being increasingly used and having the potential to become a standard of care. Encouraging long-term survival rates were reported in the context of a multidisciplinary approach. Younger ages are associated with worse survival. Perioperative chemotherapy in the context of a patient diagnosed with SM of CRC origin appears to be a reasonable option, although the present study failed to show any significant impact on long-term survival.PMID:38673636 | DOI:10.3390/jcm13082362 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 27, 2024 Category: Cancer & Oncology Authors: Beatrice Mihaela Tivadar Traian Dumitrascu Catalin Vasilescu Source Type: research
The multidisciplinary management of locally advanced rectal cancer
Expert Rev Anticancer Ther. 2024 Apr 26. doi: 10.1080/14737140.2024.2349137. Online ahead of print.ABSTRACTINTRODUCTION: . The classic paradigm for the management of locally advanced rectal cancer (LARC) consists of (chemo)radiotherapy (C)RT), total mesorectal excision and adjuvant chemotherapy (CHT). At present, due to the high rate of distant metastasis (up to 30%), the total neoadjuvant therapy (TNT) with the administration of systemic CHT in the neoadjuvant setting has gained acceptance as standard of care.Our aim is to critically review current literature on LARC management and summarize the different approaches recen...
Source: Expert Review of Anticancer Therapy - April 27, 2024 Category: Cancer & Oncology Authors: Francesca De Felice Michelangelo Miccini Andrea Botticelli Michela Roberto Niccol ò Petrucciani Source Type: research
Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients
ConclusionPlaying an essential role in regulatingTACR1 expression, gene polymorphisms ofTACR1 serve as the potential pharmacogenetic predictors of response to the NK-1 receptor antagonist-based, triple antiemetic regimens. If clinically approved, modifying the NK-1 receptor antagonist dose leads to better management of CINV in risk-allele carriers. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - April 27, 2024 Category: Cancer & Oncology Source Type: research
An integrated view of cisplatin-induced nephrotoxicity, hepatotoxicity, and cardiotoxicity: characteristics, common molecular mechanisms, and current clinical management
AbstractCisplatin (CP) is a chemotherapy drug widely prescribed to treat various neoplasms. Although fundamental for the therapeutic action of the drug, its cytotoxic mechanisms trigger adverse effects in several tissues, such as the kidney, liver, and heart, which limit its clinical use. In this sense, studies point to an essential role of damage to nuclear and mitochondrial DNA associated with oxidative stress, inflammation, and apoptosis in the pathophysiology of tissue injuries. Due to the limitation of effective preventive and therapeutic measures against CP-induced toxicity, new strategies with potential cytoprotecti...
Source: Clinical and Experimental Nephrology - April 27, 2024 Category: Urology & Nephrology Source Type: research
Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature
ConclusionThe conversion therapy protocol combined with HIPEC, XELOX chemotherapy, and anti-PD-1 therapy and our scientific, accurate, full-course management strategy may be propagable for potentially curing patients with advanced GC with PM. (Source: Journal of Gastrointestinal Cancer)
Source: Journal of Gastrointestinal Cancer - April 27, 2024 Category: Cancer & Oncology Source Type: research
Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care
ConclusionA considerable proportion of patients with TN and HER2-positive breast cancer do not receive NAC as first treatment. Of those, most were not assessed by both a surgeon and medical oncologist prior to initiating therapy. This points toward potential gaps in multidisciplinary assessment and disparities in receipt of guideline-concordant care. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 27, 2024 Category: Cancer & Oncology Source Type: research
Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer: A systematic review and pooled meta-analysis to determine the preferred regimen
To determine whether neoadjuvant gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical cystectomy improves overall survival (OS), progression-free survival (PFS), and pathologic complete response (pCR) for patients with muscle-invasive bladder cancer (MIBC) with secondary analyses of pathological downstaging and toxicity. (Source: Urology)
Source: Urology - April 27, 2024 Category: Urology & Nephrology Authors: Corbin J. Eule, Adam Warren, Elizabeth Molina Kuna, Eryn B. Callihan, Simon P. Kim, Thomas W. Flaig Source Type: research
Outcomes of a Formal Hematopoietic Cell Transplantation (HCT) Survivorship Program on Screening for Late Effects
Advances in the treatment of hematologic malignancies, allogeneic hematopoietic cell transplantation (HCT), and supportive care continue to improve post-HCT outcomes, and the number of long-term HCT survivors in the past decade has dramatically increased.1,2 With improved post-HCT survival, it is increasingly important to consider late-treatment effects from chemotherapy and/or radiation and chronic graft-vs-host disease (GVHD) which may lead to decrements in quality of life (QOL) and survival,3 –5 especially since life expectancy post-HCT remains lower than that of the general population. (Source: Biology of Blood and M...
Source: Biology of Blood and Marrow Transplantation - April 27, 2024 Category: Hematology Authors: Richard A. Newcomb, Lucy Gao, Julie Vanderklish, Alexandra Tse, Meredith Saylor, Colleen Danielson, Nisha Wali, Matthew Frigault, Steven McAfee, Thomas Spitzer, Zachariah DeFilipp, Yi-Bin Chen, Hermioni L. Amonoo, Areej El-Jawahri Source Type: research
Cancers, Vol. 16, Pages 1705: Survivin as a Therapeutic Target for the Treatment of Human Cancer
ene
Survivin was initially identified as a member of the inhibitor apoptosis (IAP) protein family and has been shown to play a critical role in the regulation of apoptosis. More recent studies showed that survivin is a component of the chromosome passenger complex and acts as an essential mediator of mitotic progression. Other potential functions of survivin, such as mitochondrial function and autophagy, have also been proposed. Survivin has emerged as an attractive target for cancer therapy because its overexpression has been found in most human cancers and is frequently associated with chemotherapy resistance, recurr...
Source: Cancers - April 27, 2024 Category: Cancer & Oncology Authors: Qiang Wang Mark I. Greene Tags: Review Source Type: research
Cancers, Vol. 16, Pages 1703: Targeting TRPV4 Channels for Cancer Pain Relief
Trevisan
Despite the unique and complex nature of cancer pain, the activation of different ion channels can be related to the initiation and maintenance of pain. The transient receptor potential vanilloid 4 (TRPV4) is a cation channel broadly expressed in sensory afferent neurons. This channel is activated by multiple stimuli to mediate pain perception associated with inflammatory and neuropathic pain. Here, we focused on summarizing the role of TRPV4 in cancer etiology and cancer-induced pain mechanisms. Many studies revealed that the administration of a TRPV4 antagonist and TRPV4 knockdown diminishes nociception in ...
Source: Cancers - April 27, 2024 Category: Cancer & Oncology Authors: Caren Tatiane de David Antoniazzi N áthaly Andrighetto Ruviaro Diulle Spat Peres Patr ícia Rodrigues Fernanda Tibolla Viero Gabriela Trevisan Tags: Review Source Type: research
Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
CONCLUSIONS: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.PMID:38669521 | DOI:10.3233/CBM-230301 (Source: Cancer Biomarkers : Section A of Disease Markers)
Source: Cancer Biomarkers : Section A of Disease Markers - April 26, 2024 Category: Cancer & Oncology Authors: Nozomu Kimura Yoko Tsukita Risa Ebina-Shibuya Eisaku Miyauchi Mitsuhiro Yamada Daisuke Narita Ryota Saito Chihiro Inoue Naoya Fujino Tomohiro Ichikawa Tsutomu Tamada Hisatoshi Sugiura Source Type: research
Longitudinal brain volumetrics in glioma survivors
CONCLUSIONS: This study demonstrated volume loss in contralateral brain structures among LGG survivors, and patients who received RT experienced greater volume loss than those who did not. The results of this study may help to provide context for cognitive outcome research in LGG survivors and inform the design of future strategies to preserve cognition.PMID:38669700 | DOI:10.3171/2024.1.JNS231980 (Source: Journal of Neurosurgery)
Source: Journal of Neurosurgery - April 26, 2024 Category: Neurosurgery Authors: Andrew M McDonald Donna L Murdaugh Katherine A Heinzman Rex A Cardan Jessica Jacob John B Fiveash L Burt Nabors Courtney A Cooper John M Hoyle Desmin Milner Carlos E Cardenas Source Type: research
Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
CONCLUSIONS: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.PMID:38669521 | DOI:10.3233/CBM-230301 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - April 26, 2024 Category: Cancer & Oncology Authors: Nozomu Kimura Yoko Tsukita Risa Ebina-Shibuya Eisaku Miyauchi Mitsuhiro Yamada Daisuke Narita Ryota Saito Chihiro Inoue Naoya Fujino Tomohiro Ichikawa Tsutomu Tamada Hisatoshi Sugiura Source Type: research
Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients
Curr Oncol. 2024 Apr 17;31(4):2274-2277. doi: 10.3390/curroncol31040168.ABSTRACTMaintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with Leishmania amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphoteric...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Sophie Laroumagne Julie Tronchetti Herv é Dutau Philippe Astoul Source Type: research
Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data
This study used Pentavere's previously validated artificial intelligence (AI) to extract real-world data on the treatment patterns and outcomes of patients receiving CDK4/6i+endocrine therapy (ET) for HR+/HER2- ABC/MBC at Sinai Health in Toronto, Canada. Between 1 January 2016 and 1 July 2021, 48 patients were diagnosed with HR+/HER2- ABC/MBC and received CDK4/6i + ET. A total of 38 out of 48 patients received CDK4/6i + ET in 1L, of which 34 of the 38 (89.5%) received palbociclib + ET. In 2L, 12 of the 21 (57.1%) patients received CDK4/6i + ET, of which 58.3% received abemaciclib. In 3L, most patients received chemotherapy...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Ruth Moulson Guillaume Feug ère Tracy S Moreira-Lucas Florence Dequen Jessica Weiss Janet Smith Christine Brezden-Masley Source Type: research
